[go: up one dir, main page]

DK3533787T3 - Pyridonforbindelse som C-MET-hæmmer - Google Patents

Pyridonforbindelse som C-MET-hæmmer Download PDF

Info

Publication number
DK3533787T3
DK3533787T3 DK17864813.5T DK17864813T DK3533787T3 DK 3533787 T3 DK3533787 T3 DK 3533787T3 DK 17864813 T DK17864813 T DK 17864813T DK 3533787 T3 DK3533787 T3 DK 3533787T3
Authority
DK
Denmark
Prior art keywords
met inhibitor
pyridone compound
pyridone
compound
inhibitor
Prior art date
Application number
DK17864813.5T
Other languages
English (en)
Inventor
Xiongbin Xu
Gang Li
Charles Z Ding
Lihong Hu
Guoping Hu
Jian Li
Shuhui Chen
Zhigang Chi
Kun Wang
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62024383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3533787(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3533787T3 publication Critical patent/DK3533787T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK17864813.5T 2016-10-27 2017-10-27 Pyridonforbindelse som C-MET-hæmmer DK3533787T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610954377 2016-10-27
PCT/CN2017/107964 WO2018077227A1 (zh) 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物

Publications (1)

Publication Number Publication Date
DK3533787T3 true DK3533787T3 (da) 2020-11-30

Family

ID=62024383

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17864813.5T DK3533787T3 (da) 2016-10-27 2017-10-27 Pyridonforbindelse som C-MET-hæmmer

Country Status (28)

Country Link
US (1) US10501443B2 (da)
EP (1) EP3533787B1 (da)
JP (1) JP6719679B2 (da)
KR (1) KR102070748B1 (da)
CN (1) CN109311812B (da)
AU (1) AU2017348810B2 (da)
BR (1) BR112019008415B1 (da)
CA (1) CA3041164C (da)
CO (1) CO2019005165A2 (da)
DK (1) DK3533787T3 (da)
EA (1) EA038108B1 (da)
ES (1) ES2835301T3 (da)
HR (1) HRP20201985T1 (da)
HU (1) HUE051734T2 (da)
IL (1) IL266126B (da)
LT (1) LT3533787T (da)
MX (1) MX374439B (da)
MY (1) MY189557A (da)
PE (1) PE20190912A1 (da)
PH (1) PH12019500875B1 (da)
PL (1) PL3533787T3 (da)
PT (1) PT3533787T (da)
RS (1) RS61126B1 (da)
SG (1) SG11201903801YA (da)
SI (1) SI3533787T1 (da)
UA (1) UA122737C2 (da)
WO (1) WO2018077227A1 (da)
ZA (1) ZA201903074B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278281B2 (en) 2018-04-26 2025-01-01 Fujian Cosunter Pharmaceutical Co Ltd Crystalline form of C–MET inhibitor and its salt form and method for preparing them
US11442063B2 (en) * 2018-05-30 2022-09-13 Promega Corporation Broad spectrum kinase binding agents
WO2020156453A1 (zh) * 2019-02-01 2020-08-06 南京明德新药研发有限公司 作为c-Met抑制剂的含嘧啶基团的三并环类化合物
CN116171156B (zh) * 2020-07-31 2025-07-04 江苏奥赛康药业有限公司 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
CA3222061A1 (en) 2021-06-04 2022-12-08 Merck Patent Gmbh Compounds for the treatment of glioblastoma
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586418B2 (en) * 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
JPWO2005085200A1 (ja) 2004-03-05 2008-01-17 萬有製薬株式会社 ピリドン誘導体
AU2008219166B2 (en) * 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
EP2768826A1 (de) 2011-10-17 2014-08-27 Bayer Intellectual Property GmbH Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
CA2867637A1 (en) * 2012-03-19 2013-09-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
EP2906294B1 (en) * 2012-10-11 2018-04-18 Merck Patent GmbH Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor
AU2015360006B2 (en) * 2014-12-11 2020-07-16 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative

Also Published As

Publication number Publication date
PL3533787T3 (pl) 2021-03-08
CN109311812A (zh) 2019-02-05
CA3041164C (en) 2019-12-17
WO2018077227A1 (zh) 2018-05-03
CN109311812B (zh) 2020-03-17
LT3533787T (lt) 2020-11-25
ES2835301T3 (es) 2021-06-22
IL266126A (en) 2019-06-30
EP3533787A4 (en) 2019-11-13
EA201990952A1 (ru) 2019-11-29
EP3533787B1 (en) 2020-09-30
ZA201903074B (en) 2020-01-29
PH12019500875B1 (en) 2024-03-01
JP6719679B2 (ja) 2020-07-08
MY189557A (en) 2022-02-16
BR112019008415A2 (pt) 2019-07-09
KR102070748B1 (ko) 2020-01-29
US20190248763A1 (en) 2019-08-15
RS61126B1 (sr) 2020-12-31
AU2017348810B2 (en) 2020-05-07
EA038108B1 (ru) 2021-07-07
MX374439B (es) 2025-03-06
EP3533787A1 (en) 2019-09-04
HUE051734T2 (hu) 2021-03-29
HRP20201985T1 (hr) 2021-02-05
AU2017348810A1 (en) 2019-05-23
MX2019004626A (es) 2019-11-08
SG11201903801YA (en) 2019-05-30
JP2019535806A (ja) 2019-12-12
CO2019005165A2 (es) 2019-05-31
UA122737C2 (uk) 2020-12-28
PE20190912A1 (es) 2019-06-26
CA3041164A1 (en) 2018-05-03
SI3533787T1 (sl) 2021-01-29
IL266126B (en) 2020-07-30
BR112019008415B1 (pt) 2020-09-29
KR20190058678A (ko) 2019-05-29
NZ753020A (en) 2021-08-27
US10501443B2 (en) 2019-12-10
PH12019500875A1 (en) 2019-06-17
PT3533787T (pt) 2020-11-20

Similar Documents

Publication Publication Date Title
IL286839A (en) Propyne-indole compounds
DK3728252T3 (da) 4-azaindolforbindelser
DK3533787T3 (da) Pyridonforbindelse som C-MET-hæmmer
DK3472167T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3381918T3 (da) 7-(Thiazol-5-yl)-pyrrolopyrimidinforbindelse som TLR7-agonist
DK3390395T3 (da) Forbindelser, der kan anvendes som kinase-inhibitorer
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3466949T3 (da) Tricyklisk forbindelse som anticancermidler
DK3519398T3 (da) Pyridinforbindelse
DK3533796T3 (da) Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK3256462T3 (da) Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3638680T3 (da) Heteroaromatiske forbindelser som vanininhibitorer
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3562487T3 (da) Metalloenzyminhibitorforbindelser